These medicines are used as standard treatments for advanced or metastatic NSCLC patients with no driver oncogenes (e.g., epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK)) [4]. This evidence concerns the gene ALK and non-small cell lung carcinoma.